Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986360 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS-986360 | EXPERIMENTAL | - |
| BMS-986360 + Docetaxel | EXPERIMENTAL | - |
| BMS-986360 + Nivolumab | EXPERIMENTAL | - |
| BMS-986360 + Capecitabine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986360 | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participants in Part 1 must have histologic or cytologic confirmation of non-small cell lung cancer (NSCLC), metastatic triple negative breast cancer (mTNBC), squamous cell carcinoma of head and neck (SCCHN), pancreatic adenocarcinoma (PAAD), renal cell carcinoma (RCC), micros...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986360 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development. The drug is being evaluated alone and in combination with chemotherapy or nivolumab in patients with advanced solid tumors.
BMS-986360 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
BMS-986360 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of the drug has been completed, evaluating it alone and in combination with chemotherapy or nivolumab in advanced solid tumors.
BMS-986360 has been studied in a Phase 1 clinical trial with the identifier NCT05625412. This trial evaluated the drug alone and in combination with chemotherapy or nivolumab in patients with advanced solid tumors. The trial enrolled 70 participants and has been completed.
Yes, BMS-986360 is also known as CC-90001. The clinical trial NCT05625412 refers to the drug as BMS-986360/CC-90001, indicating that both names refer to the same investigational agent being studied for advanced solid tumors.